-transparent.png){kind=logo}
Monoamine oxidase-B (MAO-B) has been determined to be the enzyme responsible for the conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into its toxic metabolite 1-methyl-4-phenylpyridine ion (MPP+). Since this enzyme has been localized primarily in astrocytes and serotonergic neurons, it would appear that MPP+ is being produced outside the dopaminergic neurons. To investigate this possibility, the administration of MPTP was preceded by systemically administered fluoxetine. In keeping with its demonstrated ability to inhibit uptake into serotonergic neurons and serotonin uptake into astrocytes, fluoxetine pretreatment resulted in a significant attenuation of MPTP-induced depletions of striatal dopamine and serotonin concentration. These results support the extra-dopaminergic production of MPP+.
W J Brooks, and
M F Jarvis, and
G C Wagner
July 2003,
Journal of neurochemistry,
W J Brooks, and
M F Jarvis, and
G C Wagner
May 1992,
Annals of the New York Academy of Sciences,
W J Brooks, and
M F Jarvis, and
G C Wagner
September 1985,
Brain research,
W J Brooks, and
M F Jarvis, and
G C Wagner
November 2019,
Antioxidants (Basel, Switzerland),
W J Brooks, and
M F Jarvis, and
G C Wagner
April 2007,
The Chinese journal of physiology,
W J Brooks, and
M F Jarvis, and
G C Wagner
January 1987,
Neurochemistry international,
W J Brooks, and
M F Jarvis, and
G C Wagner
May 2008,
Experimental neurology,
W J Brooks, and
M F Jarvis, and
G C Wagner
May 2007,
Antioxidants & redox signaling,
W J Brooks, and
M F Jarvis, and
G C Wagner
January 2008,
Cell biology international,
W J Brooks, and
M F Jarvis, and
G C Wagner
September 2019,
Aging,
